NR3C2 and chronic kidney disease: Mineralocorticoid receptor activation has been investigated experimentally in renal ischaemia\reperfusion injury in rodents and the potential therapeutic use of MRAs in this setting is relevant to the hypothesis that renal ischaemia contributes to feline CKD initiation and progression (Brown et al., 2019; Cowgill et al., 2016; Jepson, 2016).